Teriparatida en el tratamiento sustitutivo del hipoparatiroidismo crónico. A propósito de un caso

Autor: Morán López JM, Crespo Gutiérrez J, Puech de Oriol M

Publikováno v: Revista de Osteoporosis y Metabolismo Mineral, Vol 14, Iss 4, Pp 104-106 (2022)

Objetivo: Comunicar la experiencia del uso de teriparatida como tratamiento sustitutivo eficaz para el hipoparatiroidismo crónico. Material y métodos: Se plantea el caso clínico de un paciente con hipoparatiroidismo crónico postquirúrgico que p

Externí odkaz: https://doaj.org/article/b397e3e3e20d4c52bcdca5f4db8cfb4f

Tratamiento del hipoparatiroidismo con hormona paratiroidea

Autor: Esteban Cardona, Carlos Alfonso Builes-Barrera, Alejandro Román-González

Publikováno v: Revista Colombiana de Endocrinología, Diabetes y Metabolismo, Vol 6, Iss 1 (2019)

El hipoparatiroidismo es un trastorno del metabolismo del calcio infrecuente. La principal etiología es la posquirúrgica en el 75% de los casos. El hipoparatiroidismo crónico tiene una prevalencia estimada de 20-40 por cada 100.000 habitantes. Las

Externí odkaz: https://doaj.org/article/b96cf4b9d5264082b5ea09f3fb93bb7b

Osteonecrosis múltiples como forma de presentación de una osteogénesis imperfecta

Autor: Lisa Gracia M, Córdoba Alonso AI, Pérez Núñez MI, Hernández Hernández JL

Publikováno v: Revista de Osteoporosis y Metabolismo Mineral, Vol 7, Iss 1, Pp 23-26 (2015)

Presentamos el caso de una paciente con osteogénesis imperfecta, que debutó como osteonecrosis múltiples. En nuestro conocimiento, es el primer caso descrito en la literatura de esta forma de presentación de la enfermedad genética. Se analiza el

Externí odkaz: https://doaj.org/article/9febdec652c2443e9190433e57eba55a

Evaluation of chronic low back pain in osteoporotic patients in treatment with teriparatide

Autor: Renata Alvarenga Nunes, Jardel Pillo Alves Teixeira, Frederico Barra de Moraes, Lindomar Guimarães Oliveira, Flávia Tandaya Grandi, Mariely Fernanda da Silva, Carlos Ney de Mesquita Júnior

Publikováno v: Coluna/Columna, Vol 13, Iss 1, Pp 20-22 (2014)

OBJECTIVE: The objective was to assess the improvement of chronic low back pain in osteoporotic patients treated with teriparatide (TPTD). METHODS: This was an observational study with a convenience sample of 21 patients with osteoporosis using TPTD,

Externí odkaz: https://doaj.org/article/2660b62c7471449aa1d63c318521f4c2

Association between proton pump inhibitors' long-term exposure and the prescription of osteoporosis drug treatment in adult patients in Colombia

Autor: Portilla Pinzón, Alfredo, Muñoz Claros, Conny Stefanny, Castro Becerra, Ricardo, Guatava Redondo, Lina Fernanda

Publikováno v: Targownik LE, Goertzen AL, Luo Y, Leslie WD. Long-Term Proton Pump Inhibitor Use Is Not Associated with Changes in Bone Strength and Structure. Am J Gastroenterol [Internet]. 2017;112(1):95–101. Available from: http://dx.doi.org/10.1038/ajg.2016.481
Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. Cmaj. 2008;179(4):319–26.
Corley DA, Kubo A, Zhao W QC. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;138(1):93–101.
Arj A, Razavi Zade M, Yavari M, Akbari H, Zamani B A. Proton pump inhibitors use and change in bone mineral density. Int J Rheum Dis. 2016;19(9):864–8.
Kumar S, Drake MT, Schleck CD, Johnson ML, Alexander JA, Katzka DA IP. Incidence and predictors of osteoporotic fractures in patients with Barrett’s oesophagus: a population-based nested case-control study. Aliment Pharmacol Ther. 2017;46(11–12):1094–102.
Ghosh G, Schnoll-Sussman F, Mathews S KP. Reported proton pump inhibitor side effects: what are physician and patient perspectives and behaviour patterns? Aliment Pharmacol Ther. 2020;51(11):121–8.
Medina Orjuela A, Rosero Olarte Ó, Nel P, Plata R, Sánchez Escobar F, Chalem Choueka M, et al. Consenso Colombiano De Osteoporosis. Rev Colomb Reumatol. 2018;25(3):184–210.
Kaye JA JH. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28(8):951–9.
Lin SM, Yang SH, Liang CC HH. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study. Osteoporos Int. 2018;29(1):153–62.
Jacob L, Hadji P KK. The use of proton pump inhibitors is positively associated with osteoporosis in postmenopausal women in Germany. Climacteric. 2016;19(5):478–81.
Solomon DH, Diem SJ, Ruppert K, Lian YJ, Liu CC, Wohlfart A, Greendale GA FJ. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. J Bone Min Res. 2015;30(2):232–9.
Bahtiri E, Islami H, Hoxha R, Qorraj-Bytyqi H, Rexhepi S, Hoti K, Thaçi K, Thaçi S KÇ. Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors. J Bone Min Metab. 2016;34(5):571–9.
Hansen KE, Nieves JW, Nudurupati S, Metz DC PM. Dexlansoprazole and Esomeprazole Do Not Affect Bone Homeostasis in Healthy Postmenopausal Women. Gastroenterology. 2016;156(4):926–34.
Maes ML, Fixen DR LS. Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf. 2017;8(9):273–97.
Gómez MA, olivares R, Cardona H. Tratamiento empírico de la enfermedad ácido-péptica. Rev Colomb Gastroenterol. 2004;19(1):26–36.
Nash DB. The use of medicines in the united states: A detailed review. Am Heal Drug Benefits. 2012;5(7):2012.
Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Srivali N, Edmonds PJ, Ungprasert P, et al. Proton pump inhibitors linked to hypomagnesemia: A systematic review and meta-analysis of observational studies. Ren Fail. 2015;37(7):1237–41.
Park CH, Kim EH, Roh YH, Kim HY, Lee SK. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: A systematic review and meta-analysis. PLoS One. 2014;9(11).
Yang SD, Chen Q, Wei HK, Zhang F, Yang DL, Shen Y, et al. Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: A meta-analysis. Int J Clin Exp Med. 2015;8(4):4899–910.
Kwok CS, Yeong JKY, Loke YK. Meta-analysis: Risk of fractures with acid-suppressing medication. Bone [Internet]. 2011;48(4):768–76. Available from: http://dx.doi.org/10.1016/j.bone.2010.12.015
Gomm W, Von Holt K, Thomé F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: A pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410–6.
Haenisch B, von Holt K, Wiese B, Prokein J, Lange C, Ernst A, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265(5):419–28.
Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer S V., Marcus J, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10(6):1–16.
El-Charabaty E, Saifan C, Abdallah M, Naboush A, Glass D, Azzi G, et al. Effects of proton pump inhibitors and electrolyte disturbances on arrhythmias. Int J Gen Med. 2013;6:515–8.
Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: A nested case-control study. BMC Nephrol [Internet]. 2013;14(1):1. Available from: BMC Nephrology
Dirección PJ, Farmacia G De, Ministerio S, Sanidad D, Social P. Estudio de utilización de antiulcerosos en España ( 2000-2008 ). 2009;2:49–54.
Erratum: Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper (Osteoporos Int, (2012) 23, 11, (2567-2576), 10.1007/s00198-011-1870-0). Osteoporos Int. 2012;23(11):2577.
Chubineh S, Birk J. Proton pump inhibitors: The good, the bad, and the unwanted. South Med J. 2012;105(11):613–8.
Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-Pump Inhibitor Therapy Induces Acid-Related Symptoms in Healthy Volunteers After Withdrawal of Therapy. Gastroenterology [Internet]. 2009;137(1):80-87.e1. Available from: http://dx.doi.org/10.1053/j.gastro.2009.03.058
Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: A systematic review and meta-analysis of observational studies. Am J Gastroenterol [Internet]. 2011;106(7):1209–18. Available from: http://dx.doi.org/10.1038/ajg.2011.113
Eom CS, Park SM, Myung SK, Yun JM, Ahn JS. Use of acid-suppressive drugs and risk of fracture: A meta-analysis of observational studies. Ann Fam Med. 2011;9(3):257–67.
Ali T, Roberts DN, Tierney WM. Long-term Safety Concerns with Proton Pump Inhibitors. Am J Med [Internet]. 2009;122(10):896–903. Available from: http://dx.doi.org/10.1016/j.amjmed.2009.04.014
Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170(9):784–90.
Hunfeld NGM, Geus WP, Kuipers EJ. Systematic review: Rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther. 2007;25(1):39–46.
Ho PM, Maddox TM, Wang L. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA-J Am Med Assoc. 2009;301(9):937–44.
Charlot M, Ahlehoff O, Norgaard ML, Jørgensen CH, Sørensen R. Annals of Internal Medicine Proton-Pump Inhibitors Are Associated With Increased Cardiovascular Risk Independent of Clopidogrel Use. Ann Intern Med. 2010
Scott SA, Owusu Obeng A, Hulot JS. Antiplatelet drug interactions with proton pump inhibitors. Expert Opin Drug Metab Toxicol. 2014;10(2):175–89.
Morales-Torres J, Gutiérrez-Ureña S. The burden of osteoporosis in Latin America. Osteoporos Int. 2004;15(8):625–32.
Taylor Jiménez B, Piñera Andux I, Rodríguez González J, Rodríguez Soria N, López García Y. Factores de riesgo de osteoporosis en el adulto mayor. Rev Cuba Reumatol RCuR. 2009;11(13):35–43.
Aziziyeh R, Amin M, Habib M, Garcia Perlaza J, Szafranski K, McTavish RK, et al. The burden of osteoporosis in four Latin American countries: Brazil, Mexico, Colombia, and Argentina. J Med Econ [Internet]. 2019;22(7):638–44. Available from: http://dx.doi.org/10.1080/13696998.2019.1590843
Cardona-Ospina J, Medina-Morales DA, Rodríguez-Morales A, Machado-Alba J. Efectos adversos a largo plazo de los inhibidores de la bomba de protones. Perspectiva desde la medicina basada en la evidencia. Rev Colomb Gastroenterol. 2017;31(4):403.
Johnson DA, Katz PO, Armstrong D, Cohen H, Delaney BC, Howden CW, et al. The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs. 2017;77(5):547–61.
Salazar Madrigal K. Osteoporosis: un problema mayor de salud pública. Rev costarric salud pública. 2008;17(32):75–9.
Quintana Duque MA, Otero Regino W, Melgar Burbano C. Inhibidores de bomba de protones y riesgo de osteoporosis. Rev Colomb Gastroenterol. 2009;24(2):169–79.
Wertheimer A, Santella T. Problemas en el uso de Dosis Diaria Definida (DDD) como base estadística para fijar precios de medicamentos y reembolsos. Fed Int la Ind del Medicam [Internet]. 2007;(Ddd):3–20. Available from: https://www.ifpma.org/wp-content/uploads/2016/01/IFPMA_DDD_2007_SP.pdf
Abrahamsen B, Eiken P ER. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med. 2011;171(11):998–1004.
Andersen BN, Johansen PB, Abrahamsen B. Proton pump inhibitors and osteoporosis. Curr Opin Rheumatol. 2016;28(4):420–5.
Ghebremariam YT, Lependu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, et al. Unexpected effect of proton pump inhibitors: Elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845–53.
Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer. 2008;112(5):1001–10.
Agirrezabala JR, Alfonso I, Armendáriz M, Elola M, Jaio N. Inhibidores de la bomba de protones: Recomendaciones de uso. INFAC. Serv Cent Publicaciones del Gob Vasco Dep Salud. 2014;44:2431–40.
Ferrer I, Pérez JM, Herrerías JM. Guía de Seguimiento Farmacoterapéutico sobre Úlcera Péptica [Internet]. Maria Josè Faus. 2016. 56 p. Available from: https://www.ugr.es/~cts131/esp/guias/GUIA_ULCERA.pdf
aranauskaite A, Savickiene A. Osteoporosis: diagnosis, prevention and treatment. Vol. 38, Medicina (Kaunas, Lithuania). 2002.
Departamento Administrativo Nacional de Estadística DANE. PROYECCIONES DE POBLACIÓN 2005-2020. Colombia. Tablas abreviadas de mortalidad nacionales y departamentales 1985-2020. Proyecciones de población 2005-2020 [Internet]. 2007;4–22. Available from: https://www.dane.gov.co/files/investigaciones/poblacion/proyepobla06_20/8Tablasvida1985_2020.pdf%0Ahttp://www.dane.gov.co/files/investigaciones/poblacion/proyepobla06_20/8Tablasvida1985_2020.pdf
Hochberg MC. Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive Agents. J Clin Endocrinol Metab. 2002;87(4):1586–92.
Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339–47.
Ji X, Wang Y, Ma Y, Hu Z, Man S, Zhang Y, et al. Improvement of disease management and cost effectiveness in Chinese patients with ankylosing spondylitis using a smart-phone management system: A prospective cohort study. Biomed Res Int. 2019;2019.
Jódar Gimeno E. Osteoporosis secundarias. Med. 2014;11(60):3535–44.
Gómez-garcía F. Eficacia del tratamiento farmacológico de la osteoporosis en la prevención de fracturas. 2001;15(2):70–85.
Miller PD, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, et al. Cyclical Etidronate in the Treatment of Postmenopausal Osteoporosis. Am J Med [Internet]. 1997 Dec 1 [cited 2018 Nov 22];103(6):468–76. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0002934397002787
Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008;19(4):399–428.
National Institute for Health and Care. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended) | Guidance and guidelines | NICE. 2011;2008(January 2010). Available from: https://www.nice.org.uk/guidance/ta160
Álvarez Álvarez R, Mendoza Garcés F, Torre Mollinedo F, Callejo Orcasitas A, Arizaga Maguregui A. Actualización en el tratamiento de la osteoporosis. Manejo desde una unidad del dolor (1.a parte). Rev la Soc Esp del Dolor. 2014;21(6):328–37.
Gac E H. Polifarmacia y morbilidad. Rev Med Clin Condes. 2012;23(1):31–5.
Pinto J. Consenso Osteoporosis Sociedad Gallega de Reumatología. 2014;75(1):S1–3.
Verdejo-Bravo C, Calleja-Panero JL, Guillén-Llera F, Ribera-Casado JM. Estudio epidemiológico sobre la enfermedad ácido-péptica en pacientes ancianos ambulatorios. Rev Esp Geriatr Gerontol [Internet]. 2006;41(1):21–8. Available from: http://www.sciencedirect.com/science/article/pii/S0211139X06729195
Pértegas Diaz S, Pita Fernandez S. Cálculo del tamaño muestral para la determinación de factores pronósticos. Cad Aten Primaria. 2002;9:30–3.
S.Clemente:A.Belén;M.Estrada CB. Guía de práctica Clínica.Empleo de los inhibidores de la bomba de protones en la prevención de gastropatías secundarias a fármacos. 2014;111. Available from: www.guiasalud.es/GPC/GPC_509_IBP_gastropatias_2rias_fcos_completa.pdf
Haimanot S, Hayes P, Schuster B. PPI Deprescribing. RxFiles [Internet]. 2017;2015(April 2015). Available from: http://www.rxfiles.ca/rxfiles/uploads/documents/PPI-Deprescribing-Newsletter.pdf
Reimer C. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol [Internet]. 2013;27(3):443–54. Available from: http://dx.doi.org/10.1016/j.bpg.2013.06.001
Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56(4):931–50.
Bustamante Robles KY, Ticse Aguirre R, Cánepa Rondo IF, Costta Herrera CG, Vasquez Kunze S, Soto Arquiñigo L, et al. Frecuencia de la prescripción de los inhibidores de bomba de protones basada en guías de práctica clínica en pacientes hospitalizados en dos hospitales docentes de Lima-Perú. Rev Gastroenterol del Perú. 2012;32(1):44–9.
Greenland S, Mickey RM. Re: “The impact of confounder selection criteria on effect estimation.” Am J Epidemiol. 1989;130(5):1066.
Pedrosa I, Juarros-Basterretxea J, Robles-Fernández A, Basteiro J, García-Cueto E. Pruebas de bondad de ajuste en distribuciones simétricas, ¿qué estadístico utilizar? Univ Psychol. 2014;14(1):245–54.
Jo Y, Park E, Ahn SB, Jo YK, Son B, Kim SH, Park YS KH. A Proton Pump Inhibitor’s Effect on Bone Metabolism Mediated by Osteoclast Action in Old Age: A Prospective Randomized Study. Gut Liver. 2015;9(5):607–14.
Adams AL, Black MH, Zhang JL, Shi JM JS. Proton-pump inhibitor use and hip fractures in men: a population-based case-control study. Ann Epidemiol. 2014;24(4):286–90.
Chen CH, Lin CL KC. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis. Osteoporos Int. 2016;27(6):2117–26.
Targownik LE, Lix LM, Leung S LW. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138(3):896–904.
Brozek W, Reichardt B, Zwerina J, Dimai HP, Klaushofer K ZE. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study. Osteoporos. 2017;28(5):1587–95.
Hussain S, Siddiqui AN, Habib A, Hussain MS NA. Proton pump inhibitors’ use and risk of hip fracture: a systematic review and meta-analysis. Rheumatol Int. 2018;38(11):1999–2014.
Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, Josse RG, Kaiser SM, Kovacs CS, Prior JC ZWCRG. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol. 2012;107(9):1361–9.
Freedberg DE, Haynes K, Denburg MR, Zemel BS, Leonard MB, Abrams JA YY. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. Osteoporos Int. 2015;26(10):2501–7.
Kim JJ, Jang EJ, Park J SH. Association between proton pump inhibitor use and risk of fracture: A population-based case-control study. PLoS One. 2020;15(7):023516.
Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.
van der Hoorn MMC, Tett SE, de Vries OJ, Dobson AJ PG. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study. Bone. 2015;81:675–82.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario

Introducción: En los últimos años los IBP han suscitado importante interés en la literatura médica por sus efectos adversos. Sin embargo, estudios observacionales disponibles, no permiten emitir una conclusión definitiva sobre su asociación co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce22f8db46e274f83771bb76ac494d16